The company registered sales of RON308.7 million in January-September, up 10% from RON281.2 million.
Its revenues rose 11% to RON315.5 million in the first nine months, from RON284.8 million. Overall expenses increased 12.6% to RON309 million from RON274.4 million.
Ropharma’s receivables at the end of June were worth RON257.3 million, 4% higher on the year. Debts climbed by 2.3% to about RON304 million.
For 2012, the company expects sales up 12%, to RON431.5 million and net profit of RON12.8 million (EUR2.9 million), up 20% on the year.
Businessman Mihai Miron indirectly owns 35.26% of Ropharma, through Rimia Investments (20.23%) and ADD Pharmaceuticals (17.72%). USA-registered Arrow Pharmaceuticals controls 31.31% of the company’s stock. Fondul de Pensii Administrat Privat ING, the largest local private pension fund, owns 5.5% of Ropharma.
Ropharma has a share capital of RON29.1 million, split into 291 million shares with a face value of RON0.1.
On the Bucharest stock market Wednesday, Ropharma closed up 0.97% to RON0.626. (EUR1=RON4.5358)